Experienced in Unicentric Castleman Disease (UCD)

Dr. John E. Godwin

Hematology | Hematology Oncology

4805 Ne Glisan St Ste 6n40,

Portland, OR

Experienced in Unicentric Castleman Disease (UCD)

4805 Ne Glisan St Ste 6n40,

Portland, OR

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Godwin is a Hematologist and a Hematologist Oncology provider in Portland, Oregon. Dr. Godwin is rated as an Experienced provider by MediFind in the treatment of Unicentric Castleman Disease (UCD). His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Melanoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Hematology Oncology

Licenses

Internal Medicine in OR

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Humana

HMO
INDEMNITY
POS
PPO

Locations

4805 Ne Glisan St Ste 6n40, Portland, OR 97213

Call: 503-215-5696

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Enrollment Status: Terminated

Publish Date: August 28, 2025

Intervention Type: Drug

Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim

Study Phase: Phase 2

Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: July 10, 2025

Intervention Type: Drug

Study Drug: MEDI0562

Study Phase: Phase 1

Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)

Enrollment Status: Active_not_recruiting

Publish Date: July 10, 2025

Intervention Type: Procedure, Drug, Radiation

Study Drug: Nivolumab

Study Phase: Phase 1/Phase 2

A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: July 10, 2025

Intervention Type: Drug

Study Drugs: MK-3475, Gemcitabine

Study Phase: Phase 1/Phase 2

A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 17, 2025

Intervention Type: Drug, Dietary supplement

Study Drugs: Cyclophosphamide, Indomethacin, Omeprazole

Study Phase: Phase 1

Intratumoral Ipilimumab in Head and Neck Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 10, 2025

Intervention Type: Drug

Study Drug: Ipilimumab

Study Phase: Phase 1

A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: March 10, 2025

Intervention Type: Drug

Study Drugs: Pembrolizumab, Paclitaxel, Capecitabine

Study Phase: Phase 1/Phase 2

Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: March 10, 2025

Intervention Type: Drug, Procedure

Study Drugs: LY2157299, Capecitabine, Fluorouracil

Study Phase: Phase 2

A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 10, 2025

Intervention Type: Drug

Study Drugs: Nivolumab, Ipilimumab, Bicalutamide

Study Phase: Phase 2

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting

Enrollment Status: Completed

Publish Date: February 27, 2025

Intervention Type: Biological

Study Drug: lisocabtagene maraleucel

Study Phase: Phase 2

Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma

Enrollment Status: Completed

Publish Date: February 07, 2024

Intervention Type: Drug, Procedure

Study Drug: MEDI6469 Anti-OX40 Antibody

Study Phase: Phase 1

A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)

Enrollment Status: Terminated

Publish Date: January 30, 2024

Intervention Type: Biological, Drug

Study Drug: Flotetuzumab

Study Phase: Phase 1/Phase 2

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

Enrollment Status: Completed

Publish Date: December 20, 2023

Intervention Type: Biological

Study Drug: Lisocabtagene maraleucel

Study Phase: Phase 2

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.

Enrollment Status: Completed

Publish Date: June 05, 2023

Intervention Type: Drug

Study Drugs: Galactoarabino-Rhamnogalactouronate, Pembrolizumab

Study Phase: Phase 1

Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer

Enrollment Status: Terminated

Publish Date: February 14, 2022

Intervention Type: Drug

Study Drug: MEDI6469

Study Phase: Phase 1

A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer

Enrollment Status: Unknown

Publish Date: September 16, 2020

Intervention Type: Device

Study Phase: Not Applicable

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Enrollment Status: Completed

Publish Date: March 21, 2019

Intervention Type: Biological

Study Phase: Phase 1

A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)

Enrollment Status: Terminated

Publish Date: February 12, 2019

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Enrollment Status: Terminated

Publish Date: December 12, 2018

Intervention Type: Drug

Study Phase: Phase 3

A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer

Enrollment Status: Completed

Publish Date: October 11, 2018

Intervention Type: Drug, Biological

Study Phase: Phase 1

Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas

Enrollment Status: Completed

Publish Date: August 17, 2018

Intervention Type: Biological, Drug

Study Phase: Phase 1

Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer

Enrollment Status: Completed

Publish Date: August 17, 2018

Intervention Type: Drug

Study Phase: Phase 1

Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC

Enrollment Status: Completed

Publish Date: July 06, 2017

Intervention Type: Drug, Biological

Study Phase: Phase 2

View 22 Less Clinical Trials

30 Total Publications

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.

Journal: Blood advances

Published: November 05, 2024

View All 30 Publications

Similar Doctors

Advanced in Unicentric Castleman Disease (UCD)

Dr. Richard T. Maziarz

Hematology Oncology | Oncology | Hematology

Advanced in Unicentric Castleman Disease (UCD)

Dr. Richard T. Maziarz

Hematology Oncology | Oncology | Hematology

University Professional Services

3303 S Bond Ave,

Portland, OR

(4.4 miles away)

503-494-8311

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Richard Maziarz is a Hematologist Oncology specialist and an Oncologist in Portland, Oregon. Dr. Maziarz is rated as a Distinguished provider by MediFind in the treatment of Unicentric Castleman Disease (UCD). His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Maziarz is currently accepting new patients.

Experienced in Unicentric Castleman Disease (UCD)

Dr. Magdolna M. Solti

Hematology Oncology | Hematology

Experienced in Unicentric Castleman Disease (UCD)

Dr. Magdolna M. Solti

Hematology Oncology | Hematology

Northwest Cancer Specialists PC

265 N Broadway,

Portland, OR

(3.4 miles away)

503-280-1223

Languages Spoken:

English, Hungarian

See accepted insurances

Accepting New Patients

Offers Telehealth

Magdolna Solti is a Hematologist Oncology specialist and a Hematologist in Portland, Oregon. Dr. Solti is rated as a Distinguished provider by MediFind in the treatment of Unicentric Castleman Disease (UCD). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, and Multiple Myeloma. Dr. Solti is currently accepting new patients.

Experienced in Unicentric Castleman Disease (UCD)

Dr. Xing-yue S. He

Hematology Oncology | Hematology | Oncology

Experienced in Unicentric Castleman Disease (UCD)

Dr. Xing-yue S. He

Hematology Oncology | Hematology | Oncology

Legacy Salmon Creek Hospital

700 Ne 87th Ave, Suite 360,

Vancouver, WA

(6.1 miles away)

360-896-7070

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Xing-yue He is a Hematologist Oncology specialist and a Hematologist in Vancouver, Washington. Dr. He is rated as an Advanced provider by MediFind in the treatment of Unicentric Castleman Disease (UCD). His top areas of expertise are Childhood Iron Deficiency Anemia, Colorectal Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast. Dr. He is currently accepting new patients.

VIEW MORE UNICENTRIC CASTLEMAN DISEASE (UCD) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Godwin's expertise for a condition

ConditionClose